Videos for Advance Care Planning in Young Adults

Status Completed

Clinical Trial Summary

This study is a randomized trial of adolescent and young adults with advanced cancer and their caregivers to assess preferences for care in advanced cancer. This research study is examining the similarities and differences between patient's and caregiver's goals of cancer care. The names of the study interventions involved in this study may include: - Questionnaires - Video - Phone Interview

Clinical Trial Description

The research study procedures include: screening for eligibility and study interventions including questionnaires and follow up visits. - Patients and their caregivers will be randomized into the same group; either ACP video decision aid intervention or usual care. - Patients' and caregivers' knowledge, preferences (goals of care, CPR, ventilation), and decisional conflict be assessed before and after the ACP video decision aid intervention or usual care. - Participants will be in this research study for up to 3 months with only 2 study visits. - It is expected that about 100 people (50 patients and 50 caregivers) will take part in this research study. ;

Study Design

Related Conditions & MeSH terms

Advanced Cancer

Clinical Trial Details

NCT number	NCT04149704
Study type	Interventional
Source	Dana-Farber Cancer Institute
Contact
Status	Completed
Phase	N/A
Start date	December 13, 2019
Completion date	May 5, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Completed	`NCT01197170` - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	Phase 1
Recruiting	`NCT05045040` - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions	N/A
Active, not recruiting	`NCT05060432` - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03994601` - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Completed	`NCT01393990` - A Study of LY2228820 in Participants With Advanced Cancer	Phase 1
Completed	`NCT02857270` - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Phase 1
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT04121676` - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer	Phase 1
Active, not recruiting	`NCT03177291` - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Active, not recruiting	`NCT03674567` - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab	Phase 1/Phase 2
Recruiting	`NCT04823377` - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.	N/A
Completed	`NCT02778126` - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer	Phase 1
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Completed	`NCT02507544` - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	Phase 1
Completed	`NCT02245204` - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Completed	`NCT01583777` - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer	Phase 1